Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients

The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune check...

Full description

Bibliographic Details
Main Authors: Anastasios Gkountakos, Pietro Delfino, Rita T. Lawlor, Aldo Scarpa, Vincenzo Corbo, Emilio Bria
Format: Article
Language:English
Published: SAGE Publishing 2021-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211006947

Internet

https://doi.org/10.1177/17588359211006947

Similar Items